{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:27:42Z","timestamp":1777530462576,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare LDL-C reduction using evolocumab 140 mg once every 2 weeks (Q2W) or 420 mg monthly (QM) versus lower doses (70 mg Q2W or 280 mg QM) or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients received evolocumab 70 or 140 mg Q2W, 280 or 420 mg QM, or placebo Q2W or QM in two 12-week phase 2 studies: one with and one without statins. Changes from baseline in LDL-C were compared across Q2W doses and across QM doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The analysis included 741 patients. Mean (95% confidence interval [CI]) reduction in LDL-C across Q2W visits through week 12 was 63.0% (60.3% to 65.7%) for evolocumab 140 mg Q2W, compared to 41.3% (38.6% to 44.0%) for 70 mg Q2W and 1.9% (4.6% reduction to 0.8% increase) for placebo Q2W (each P &lt; .001 vs 140 mg Q2W), and 62.7% (60.1% to 65.3%) for 420 mg QM, compared to 55.5% (52.9% to 58.0%) for 280 mg QM and 2.5% (5.1% reduction to 0.1% increase) for placebo QM (each P &lt; .001 vs 420 mg QM). Similar results were observed at the mean of weeks 10 and 12. In a subgroup (n = 151) with weekly assessments from weeks 8 to 12, mean (95% CI) peak effect on LDL-C reduction was 72.8% (67.7% to 77.9%) for 140 mg Q2W and 69.0% (63.6% to 74.3%) for 420 mg QM. Trough effect at week 12 underestimated LDL-C reduction. Median peak\u2013trough variability was 20.5%, 21.1%, 31.9%, and 35.1% for evolocumab 140 mg Q2W, 420 mg QM, 70 mg Q2W, and 280 mg QM, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Evolocumab 140 mg Q2W and 420 mg QM yielded similar LDL-C reduction. These doses sustained maximal LDL-C reduction, resulting in greater stability in LDL-C reduction over the dosing interval compared to lower doses. These results support evolocumab doses of either 140 mg Q2W or 420 mg QM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1074248418774043","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T22:29:37Z","timestamp":1526509777000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals"],"prefix":"10.1177","volume":"23","author":[{"given":"Scott M.","family":"Wasserman","sequence":"first","affiliation":[{"name":"Global Development, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Koren","sequence":"additional","affiliation":[{"name":"Jacksonville Center for Clinical Research, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason C.","family":"Legg","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice G.","family":"Emery","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Doshi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"bibr1-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu085"},{"key":"bibr2-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"bibr3-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.018"},{"key":"bibr4-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4030"},{"key":"bibr5-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"bibr6-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"bibr7-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"bibr8-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"bibr9-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"bibr10-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.986"},{"key":"bibr11-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903849106"},{"key":"bibr12-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61914-5"},{"key":"bibr13-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"bibr14-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.840"},{"key":"bibr15-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61771-1"},{"key":"bibr16-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22014"},{"issue":"9858","key":"bibr17-1074248418774043","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano RP","year":"2012","journal-title":"Lancet"},{"key":"bibr18-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"bibr19-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.079"},{"key":"bibr20-1074248418774043","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28719"},{"key":"bibr21-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1126\/science.1125884"},{"key":"bibr22-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0620-7"},{"issue":"1","key":"bibr23-1074248418774043","first-page":"1048","volume":"36","author":"Mahlof E","year":"2015","journal-title":"Eur Heart J"},{"key":"bibr24-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.5395"},{"key":"bibr25-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"bibr26-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"bibr27-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985"},{"key":"bibr28-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000134621.14315.43"},{"key":"bibr29-1074248418774043","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-7-22"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418774043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248418774043","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418774043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:48Z","timestamp":1777394568000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/1074248418774043"}},"subtitle":["Biological Insights and Treatment Implications"],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1177\/1074248418774043"],"URL":"https:\/\/doi.org\/10.1177\/1074248418774043","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]}}}